JT
MDGL icon

Jupiter Topco’s Madrigal Pharmaceuticals MDGL Stock Holding History

Jupiter Topco’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04B Buy
+1,936,099
New +$992M 0.42% 46

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jupiter Topco's MDGL Position: Q2 2026 in Review

Jupiter Topco opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 1,936,099 shares worth $1.04B. The stake represents 0.42% of the portfolio and ranks #46 among its holdings.

374 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Jupiter Topco held 1,936,099 shares of Madrigal Pharmaceuticals worth $1.04B as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Jupiter Topco position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.42% of Jupiter Topco's portfolio in Q2 2026, its #46 holding.
  • 374 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.